Tovecimig is a bispecific antibody that simultaneously targets Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A). This next generation angiogenic inhibitor has demonstrated clinical benefit in heavily pre-treated patients who have progressed after prior VEGF, EGFR, HER2, and PD1/L1-targeted therapies. Throughout the clinical program deep clinical responses were observed in patients with advanced biliary tract cancer, colorectal cancer, and gastric cancer. The Phase 2/3 study met its primary endpoint of overall response rate (p=0.031). The secondary endpoint analyses of progression-free survival and overall survival are expected in late Q1 of 2026.
CTX-471 is an agonistic antibody directed against the co-stimulatory molecule CD137 (4-1BB).
CD137, a member of the TNF receptor superfamily of proteins, provides a potent costimulatory signal to activated T cells and other effector cells within the innate and adaptive arms of the immune system. A CD137 signal can potentiate cytotoxic T cell and proinflammatory anti-tumor activity.
CTX-8371 is a bispecific antibody that targets simultaneously the program death receptor (PD-1) and the programmed death ligand receptor (PD-L1) expressed on immune cells and cancer cells respectively. CTX-8371 is currently enrolling patients into a Phase 1 expansion cohort in patients with non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), and Hodgins Lymphoma (HL) based on responses observed in the dose-escalation phase.
CTX-10726 is Compass’ second VEGF bispecific development candidate. The asset is a bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor A (VEGF-A). Modulation of the tumor microenvironment via VEGF targeting can improve the efficacy of immune checkpoint inhibitors, such as PD-1 blocking therapies.
In preclinical studies, CTX-10726 has demonstrated potent anti-PD-1 and anti-VEGF-A activity. CTX-10726 is currently in Phase 1 clinical development.
Compass Therapeutics is evaluating various multi-specific antibodies that simultaneously engage the angiogenesis pathway and anti-tumor immune targets including immune checkpoints, in addition to analyzing VEGF combinations with other immune response-related proteins.
*Multiple Investigator Sponsored Trials (ISTs)
1st line BTC: Tovecimig + gem / cis / durvalumab NCT06548412
1st line BTC: Tovecimig + CTX-8371 + paclitaxel
2nd line gastric cancer: Tovecimig + CTX-8371 + paclitaxel
2nd line GBM: Tovecimig + CTX-471 NCT07392957
2nd line CRC: Tovecimig + FOLFIRI NCT07662031